BACKGROUND: Egypt provides ideal conditions for poliovirus (PV) transmission (high population density, high contact rates and low sanitation and hygiene in some areas). Despite excellent program performance, wild poliovirus type 1 (PV1) continue to circulate in 2004. To investigate potential causes for the persistence, we conducted a serological study. METHODS: Seroprevalence surveys were conducted in "polio-endemic" regions (Greater Cairo and Upper Egypt) and in one control region (Lower Egypt) in December 2004. Sera collected from infants aged 6-11 months were tested for antibodies to poliovirus by neutralization assay. RESULTS: A total of 973 subjects were tested. Seroprevalence to PV type 1 (PV1), PV type 2 (PV2) and PV type 3 (PV3) was 99, 99 and 91%, respectively. Significant variation in PV3 seroprevalence was found (range: 76-100%). Region, density, maternal education, socioeconomic status (SES), stunting and diarrhea were significant risk factors for lower seroprevalence in the univariate analysis. CONCLUSIONS: Our study suggested that uniformly high immunity levels (>96%) were required to interrupt PV1 transmission in the last remaining reservoirs (last PV1 was isolated in mid-January 2005 in Egypt). It further suggests substantial regional differences in OPV immunogenicity, with rural areas and low SES achieving the lowest seroprevalence to PV3.
BACKGROUND: Egypt provides ideal conditions for poliovirus (PV) transmission (high population density, high contact rates and low sanitation and hygiene in some areas). Despite excellent program performance, wild poliovirus type 1 (PV1) continue to circulate in 2004. To investigate potential causes for the persistence, we conducted a serological study. METHODS: Seroprevalence surveys were conducted in "polio-endemic" regions (Greater Cairo and Upper Egypt) and in one control region (Lower Egypt) in December 2004. Sera collected from infants aged 6-11 months were tested for antibodies to poliovirus by neutralization assay. RESULTS: A total of 973 subjects were tested. Seroprevalence to PV type 1 (PV1), PV type 2 (PV2) and PV type 3 (PV3) was 99, 99 and 91%, respectively. Significant variation in PV3 seroprevalence was found (range: 76-100%). Region, density, maternal education, socioeconomic status (SES), stunting and diarrhea were significant risk factors for lower seroprevalence in the univariate analysis. CONCLUSIONS: Our study suggested that uniformly high immunity levels (>96%) were required to interrupt PV1 transmission in the last remaining reservoirs (last PV1 was isolated in mid-January 2005 in Egypt). It further suggests substantial regional differences in OPV immunogenicity, with rural areas and low SES achieving the lowest seroprevalence to PV3.
Authors: Aliya Yousuf; Skindar Ali Syed Shah; Imtiaz Ahmed Syed Jaffery; Syed Azher Ahmed; M A Basit Khan; Mohammad Aslam Journal: Pak J Med Sci Date: 2015 Mar-Apr Impact factor: 1.088
Authors: Mustapha Modu Gofama; Harish Verma; Hamisu Abdullahi; Natalie A Molodecky; Kehinde T Craig; Utibe-Abasi Urua; Mohammed Ashir Garba; Mohammed Arab Alhaji; William C Weldon; M Steven Oberste; Fiona Braka; Ado J G Muhammad; Roland W Sutter Journal: PLoS One Date: 2017-09-26 Impact factor: 3.240
Authors: Ali Faisal Saleem; Ondrej Mach; Farheen Quadri; Asia Khan; Zaid Bhatti; Najeeb Ur Rehman; Sohail Zaidi; William C Weldon; Steven M Oberste; Maha Salama; Roland W Sutter; Anita K M Zaidi Journal: Vaccine Date: 2015-04-24 Impact factor: 3.641
Authors: Zubairu Iliyasu; Harish Verma; Kehinde T Craig; Eric Nwaze; Amina Ahmad-Shehu; Binta Wudil Jibir; Garba Dayyabu Gwarzo; Auwalu U Gajida; William C Weldon; M Steven Oberste; Marina Takane; Pascal Mkanda; Ado J G Muhammad; Roland W Sutter Journal: Vaccine Date: 2016-08-31 Impact factor: 3.641